Search

Displaying results 4221 - 4230 of 7456 in total
  1. Drug

    Methyl pyrrolidone

    go.drugbank.com/drugs/DB12521
    Investigational

    N Methyl Pyrrolidone is under investigation for the treatment of Multiple Myeloma.

  2. Drug

    GSK-1292263

    go.drugbank.com/drugs/DB12627
    Investigational

    GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

  3. Drug

    Ataciguat

    go.drugbank.com/drugs/DB12805
    Investigational

    Ataciguat has been investigated for the basic science of Aortic Valve Stenosis.

  4. Drug

    Zotarolimus

    go.drugbank.com/drugs/DB18761
    Investigational

    Zotarolimus is an immunosuppressant under investigation for use in drug-eluting stents.

  5. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR

    Synonyms: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
  6. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    Vitex agnus-castus fruit extract is obtained from dry fruits of Vitex agnus-castus. The fruits contain mixture of iridoids, flavonoids and compounds in leaves and flowers that structurally resemble sex hormones. Clinical studies demonstr...

    Mixtures: Menopause Relief for Women
  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  9. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  10. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.